Paradigm Biopharmaceuticals Limited

Paradigm Biopharmaceuticals provides the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. Incorporated in 2014, the company is headquartered in Melbourne, Australia.